Lipocine to present clinical data on lpcn 1148 at the liver meeting® 2023

"late breaking" abstract scheduled for oral presentation on november 13 salt lake city , nov. 1, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders, today announced that an abstract on lpcn 1148 has been selected for a late breaking oral presentation at the american association for the study of liver diseases (aasld) – the liver meeting® 2023, to take place in boston ma,  november 10 to 14, 2023. presentation details title                          oral lpcn 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis presenter:                dr. arun j.
LPCN Ratings Summary
LPCN Quant Ranking